Literature DB >> 5656314

Duration of drug levels in mice as indicated by residual antileukemic efficacy.

I Kline, M Gang, D D Tyrer, N Mantel, J M Venditti, A Goldin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 5656314     DOI： 10.1159/000220528

Source DB:  PubMed          Journal:  Chemotherapia (Basel)        ISSN： 0366-7170


× No keyword cloud information.
  10 in total

1.  The usefulness of cyclophosphamide pretreatment for subrenal capsule assay against human esophageal cancer.

Authors:  M Terashima; K Ikeda; S Kawamura; C Maesawa; K Ishida; M Sato; K Saito
Journal:  Jpn J Surg       Date:  1991-03

2.  Regional lymph node x-radiation suppresses allograft rejection.

Authors:  H C Maguire; B D Jaffee
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

3.  Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models.

Authors:  Yingjen Jeffrey Wu; Leslie L Muldoon; Dana Thomas Dickey; Seth J Lewin; Csanad G Varallyay; Edward A Neuwelt
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

4.  Susceptibility of mice treated with cyclophosphamide to lethal infection with Leptospira interrogans Serovar pomona.

Authors:  B Adler; S Faine
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

5.  Growth response of B16 melanoma to in vivo treatment with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) at the initial stage after tumor transplantation.

Authors:  X H Li; G Paulus; G Atassi; N Buyssens
Journal:  Am J Pathol       Date:  1984-06       Impact factor: 4.307

6.  The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

Authors:  L Kwong; D G Kilburn; H S Teh
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.

Authors:  Serk In Park; Jinhui Liao; Janice E Berry; Xin Li; Amy J Koh; Megan E Michalski; Matthew R Eber; Fabiana N Soki; David Sadler; Sudha Sud; Sandra Tisdelle; Stephanie D Daignault; Jeffrey A Nemeth; Linda A Snyder; Thomas J Wronski; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

8.  In vitro microassay for biological activity of cyclophosphamide metabolites.

Authors:  D Laux; R N Lausch
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

Review 9.  T-cell modulation by cyclophosphamide for tumour therapy.

Authors:  Ellyn Hughes; Martin Scurr; Emma Campbell; Emma Jones; Andrew Godkin; Awen Gallimore
Journal:  Immunology       Date:  2018-03-09       Impact factor: 7.397

10.  Effect of dose fractionation on the enhancement by radiation or cyclophosphamide of artificial pulmonary metastases.

Authors:  J M Brown; G W Marsa
Journal:  Br J Cancer       Date:  1978-06       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.